Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.

Autor: Leohr, Jennifer, Dellva, Mary Anne, LaBell, Elizabeth, Coutant, David E., Arrubla, Jorge, Plum‐Mörschel, Leona, Zijlstra, Eric, Fukuda, Tsuyoshi, Hardy, Thomas
Předmět:
Zdroj: Diabetes, Obesity & Metabolism; Jan2024, Vol. 26 Issue 1, p215-223, 9p
Abstrakt: Aims: To compare the time to hyperglycaemia recovery after ultra rapid lispro (URLi; Lyumjev®) versus Humalog in a randomized, double‐blind crossover study. Materials and Methods: Thirty‐two adults with type 1 diabetes on continuous subcutaneous insulin infusion participated in two periods: each period included hyperglycaemia induced by a missed mealtime bolus (day 1) and by suspension of basal insulin delivery (day 2). When hyperglycaemia [plasma glucose (PG) >240 mg/dl] occurred, a correction bolus of URLi or Humalog was given and time to hyperglycaemia recovery (PG = 140 mg/dl), pharmacokinetics and glucodynamics were compared. Results: Following a missed mealtime bolus, URLi significantly reduced maximum PG (−13 mg/dl; p =.02), and produced numerically more rapid decline in PG (23 mg/dl/h; p =.07), and faster recovery from hyperglycaemia (−23 min; p =.1) versus Humalog, although differences were not significant. Following basal suspension, URLi significantly reduced maximum PG (−6 mg/dl; p =.02), and produced faster PG decline (24 mg/dl/h; p <.001) and faster recovery from hyperglycaemia (−16 min; p <.01) vs. Humalog. Following a correction bolus of URLi, accelerated insulin lispro absorption was observed versus Humalog: early 50% tmax was reduced by 6 or 12 min, and AUC0‐15min was increased 2.5‐ or 4.3‐fold after correction boluses by subcutaneous infusion (day 1) or injection (day 2), respectively (all p <.001). Conclusions: During episodes of hyperglycaemia commonly experienced in people with type 1 diabetes, URLi provided a faster recovery versus Humalog from a missed mealtime bolus or during basal insulin suspension. URLi shows significant acceleration of insulin absorption versus Humalog when boluses are administered by subcutaneous infusion or injection. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: